Abstract
Objective To investigate the effect of α-lipoic acid on contrast-induced nephropathy (CIN) in diabetic patients undergoing coronary angiography (CAG) or percutaneous coronary intervention (PCI).
Methods Patients diagnosed with type 2 diabetes mellitus and coronary heart disease scheduled for CAG or PCI treatment at the Department of Cardiovascular Medicine, General Hospital of Ningxia Medical University from February 1, 2021, to August 30, 2023, were recruited. After obtaining informed consent, patients were allocated into three groups: α-lipoic acid group (38 cases), adequate hydration group (60 cases), and routine hydration group (104 cases).The primary outcome observed was the incidence of CIN, and secondary endpoints included changes in SCr, TBiL, and GGT 72 hours after contrast agent administration.
Results The incidence of CIN in the α-lipoic acid group was 2.63% (1/38), 1.67% (1/60) in the adequate hydration group, and 4.81% (5/104) in the routine hydration group, with no statistically significant difference among the three groups (p=0.544). After PCI or CAG, SCr levels decreased slightly more in the α-lipoic acid group compared to the adequate hydration group, while the routine hydration group showed an increase, but the differences were not statistically significant (p> 0.05).
Conclusion α-Lipoic acid has a certain improvement effect on renal function indicators (Scr) after CAG or PCI, but it did not demonstrate a significant preventive effect on CIN. Adequate hydration showed greater reduction in oxidative stress damage after CAG or PCI compared to α-lipoic acid and routine hydration.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Natural Science Foundation of China, Grant/Award Number: 82460143 and the Scientific Research Project of Colleges and Universities of Ningxia Education Department?Grant/Award Number: NGY2018-101.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study protocol was reviewed and approved by Medical Research Ethics Review Committee of Ningxia Medical University General Hospital, (Approval number: KYLL-2021-371).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data are all available in the article.
